Switch theme
Sign up to access all valuation multiples
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
1979
389
LTM Revenue $119M
LTM EBITDA $10.7M
$417M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Surmodics has a last 12-month revenue (LTM) of $119M and a last 12-month EBITDA of $10.7M.
In the most recent fiscal year, Surmodics achieved revenue of $126M and an EBITDA of $4.7M.
Surmodics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Surmodics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $119M | XXX | $126M | XXX | XXX | XXX |
| Gross Profit | $87.1M | XXX | $54.7M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $10.7M | XXX | $4.7M | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 4% | XXX | XXX | XXX |
| EBIT | -$12.5M | XXX | -$5.6M | XXX | XXX | XXX |
| EBIT Margin | -11% | XXX | -4% | XXX | XXX | XXX |
| Net Profit | -$16.9M | XXX | -$11.5M | XXX | XXX | XXX |
| Net Margin | -14% | XXX | -9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Surmodics's stock price is $29.
Surmodics has current market cap of $415M, and EV of $417M.
See Surmodics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $417M | $415M | XXX | XXX | XXX | XXX | $-0.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Surmodics has market cap of $415M and EV of $417M.
Surmodics's trades at 3.4x EV/Revenue multiple, and 73.1x EV/EBITDA.
Equity research analysts estimate Surmodics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Surmodics has a P/E ratio of -24.5x.
See valuation multiples for Surmodics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $415M | XXX | $415M | XXX | XXX | XXX |
| EV (current) | $417M | XXX | $417M | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 39.1x | XXX | 73.1x | XXX | XXX | XXX |
| EV/EBIT | -33.3x | XXX | -50.6x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -24.5x | XXX | -30.6x | XXX | XXX | XXX |
| EV/FCF | -69.8x | XXX | -97.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSurmodics's last 12 month revenue growth is -1%
Surmodics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Surmodics's rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Surmodics's rule of X is 7% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Surmodics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | -10% | XXX | XXX | XXX |
| Rule of 40 | 9% | XXX | 4% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 7% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Surmodics acquired XXX companies to date.
Last acquisition by Surmodics was XXXXXXXX, XXXXX XXXXX XXXXXX . Surmodics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Surmodics founded? | Surmodics was founded in 1979. |
| Where is Surmodics headquartered? | Surmodics is headquartered in United States of America. |
| How many employees does Surmodics have? | As of today, Surmodics has 389 employees. |
| Who is the CEO of Surmodics? | Surmodics's CEO is Mr. Gary R. Maharaj. |
| Is Surmodics publicy listed? | Yes, Surmodics is a public company listed on NAS. |
| What is the stock symbol of Surmodics? | Surmodics trades under SRDX ticker. |
| When did Surmodics go public? | Surmodics went public in 1998. |
| Who are competitors of Surmodics? | Similar companies to Surmodics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Surmodics? | Surmodics's current market cap is $415M |
| What is the current revenue of Surmodics? | Surmodics's last 12 months revenue is $119M. |
| What is the current revenue growth of Surmodics? | Surmodics revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Surmodics? | Current revenue multiple of Surmodics is 3.5x. |
| Is Surmodics profitable? | Yes, Surmodics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Surmodics? | Surmodics's last 12 months EBITDA is $10.7M. |
| What is Surmodics's EBITDA margin? | Surmodics's last 12 months EBITDA margin is 9%. |
| What is the current EV/EBITDA multiple of Surmodics? | Current EBITDA multiple of Surmodics is 39.1x. |
| What is the current FCF of Surmodics? | Surmodics's last 12 months FCF is -$6.0M. |
| What is Surmodics's FCF margin? | Surmodics's last 12 months FCF margin is -5%. |
| What is the current EV/FCF multiple of Surmodics? | Current FCF multiple of Surmodics is -69.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
